HYBIO(SZ:300199)2022-12-06 08:10Group 1: Product Overview - Acetate Glatiramer is a key product for the company, with a global market annual sales exceeding $4 billion [2] - The product has received high recognition in the industry after years of R&D investment and technological breakthroughs [2] - The active pharmaceutical ingredient (API) received a DMF number in 2015 and completed DMF file updates by the end of 2016 [2] Group 2: Market Potential and Strategic Position - The company is actively promoting the ANDA application for Acetate Glatiramer injection in collaboration with Akorn, which is expected to positively impact future operating performance [2] - The product's successful FDA registration will significantly enhance the company's overseas market performance and improve its international sales system [2] Group 3: Liraglutide Development and Market Advantages - Liraglutide has been approved for treating type II diabetes and obesity, showing significant cardiovascular risk reduction in a large clinical trial [3] - The company has developed proprietary processes and technology for Liraglutide, achieving high product purity and quality recognized by industry experts [3] - With the expiration of the original Liraglutide patent, demand for the API is expected to grow, further boosting the company's export scale and market share in the international API market [3]